Actuate Therapeutics issues warrants covering 3M shares
The warrants may be exercised from October 28, 2026, through 5:00 p.m. New York time on October 28, 2031.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Actuate Therapeutics issued the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock at an exercise price of $0.5325 per share. The warrants were issued at the closing of the company’s public offering in consideration for a two-year lock-up of securities beneficially owned by the Bios Entities.
The three reporting persons, each identified as a director and a ten-percent owner, were Bios Fund III, LP, Bios Fund III QP, LP, and Bios Fund III NT, LP. Their reported indirect warrant acquisitions covered 126,162, 824,012, and 133,073 underlying common shares, respectively. The exercise period runs from October 28, 2026, through 5:00 p.m. New York time on October 28, 2031.
Insider Trade Summary
Grant/Award: 3,000,000 shares
Grant/Award
13 txns
Insider
BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP
Role
Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 64,995 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 87,743 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 682,885 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 194,984 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 368,304 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 47,972 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 82,018 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 36,056 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 269,342 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 82,454 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 133,073 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 824,012 | $0.00 | $0.00 |
| Grant/Award | Warrant (Right to Buy) F1, F2, F3, F4, F5 | 126,162 | $0.00 | $0.00 |
Holdings After Transaction:
Warrant (Right to Buy) — 64,995 contracts (Indirect, Directly held by Bios 2024 Co-Invest, LP);
Warrant (Right to Buy) — 87,743 contracts (Indirect, Directly held by Bios Actuate Co-Invest I, LP);
Warrant (Right to Buy) — 682,885 contracts (Indirect, Directly held by Bios Actuate Co-Invest II, LP);
Warrant (Right to Buy) — 194,984 contracts (Indirect, Directly held by Bios Actuate Co-Invest III, LP);
Warrant (Right to Buy) — 368,304 contracts (Indirect, Directly held by Bios Clinical Opportunity Fund, LP);
Warrant (Right to Buy) — 47,972 contracts (Indirect, Directly held by Bios Fund I QP, LP);
Warrant (Right to Buy) — 82,018 contracts (Indirect, Directly held by Bios Fund I, LP);
Warrant (Right to Buy) — 36,056 contracts (Indirect, Directly held by Bios Fund II NT, LP);
Warrant (Right to Buy) — 269,342 contracts (Indirect, Directly held by Bios Fund II QP, LP);
Warrant (Right to Buy) — 82,454 contracts (Indirect, Directly held by Bios Fund II, LP);
Warrant (Right to Buy) — 133,073 contracts (Indirect, Directly held by Bios Fund III NT, LP);
Warrant (Right to Buy) — 824,012 contracts (Indirect, Directly held by Bios Fund III QP, LP);
Warrant (Right to Buy) — 126,162 contracts (Indirect, Directly held by Bios Fund III, LP)
Footnotes (5)
- F1. Pursuant to a letter agreement, dated as of October 2, 2026 and amended on October 16, 2026 (the "Letter Agreement"), between Actuate Therapeutics, Inc. (the "Issuer") and Bios Partners, L.P., on behalf of certain Bios entities (the "Bios Entities"), the Bios Entities agreed to a two-year lock-up of securities of the Issuer beneficially owned by them. In consideration thereof, the Issuer agreed to issue to the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock, par value $0.000001 per share (the "Common Stock"), at an exercise price of $0.5325 per share (the "Warrants"). The Warrants were issued at the closing of the Issuer's public offering.
- F2. A Warrant may be exercised only during the period ("Exercise Period") commencing on October 28, 2026 and terminating at 5:00 P.M., New York time on October 28, 2031 ("Expiration Date"). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date.
- F3. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest.
- F4. Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
- F5. The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
Key Figures
Aggregate warrant shares: 3,000,000 shares of common stock
Warrant exercise price: $0.5325 per share
Bios Fund III warrant shares: 126,162 underlying common shares
+3 more
6 metrics
Aggregate warrant shares
3,000,000 shares of common stock
Aggregate shares the Bios Entities' warrants may purchase
Warrant exercise price
$0.5325 per share
Exercise price for the warrants
Bios Fund III warrant shares
126,162 underlying common shares
Warrants reported as indirectly acquired by Bios Fund III, LP
Bios Fund III QP warrant shares
824,012 underlying common shares
Warrants reported as indirectly acquired by Bios Fund III QP, LP
Bios Fund III NT warrant shares
133,073 underlying common shares
Warrants reported as indirectly acquired by Bios Fund III NT, LP
Lock-up period
Two years
Period the Bios Entities agreed to lock up issuer securities beneficially owned by them
Key Terms
Warrants, Exercise Period, Expiration Date, lock-up
4 terms
Warrants financial
"warrants to purchase an aggregate of 3,000,000 shares of common stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Exercise Period financial
"period commencing on October 28, 2026 and terminating at 5:00 P.M."
The exercise period is the fixed span of time during which the holder of an option or warrant can turn that contract into shares by paying the agreed strike price. Like a coupon with an expiration date, it sets a deadline for claiming the underlying stock; after it ends the right expires and is lost. For investors, the length and timing of the exercise period affect when shares may be acquired, the flexibility to act, and the contract’s practical value.
Expiration Date financial
"terminating at 5:00 P.M., New York time on October 28, 2031"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
lock-up financial
"a two-year lock-up of securities of the Issuer"
A lock-up is an agreement that prevents company insiders, early investors or employees from selling their shares for a set period after a public share offering. It matters to investors because it temporarily limits the number of shares available to trade—like a scheduled hold on extra inventory—and when that hold ends a large number of shares can enter the market, potentially putting downward pressure on the stock price and revealing insiders’ confidence in the company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do ACTU's Bios warrants expire?
The exercise period runs from October 28, 2026, through 5:00 p.m. New York time on October 28, 2031. A warrant not exercised on or before the expiration date becomes void, and its associated rights cease at close of business on that date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
